Reported value
$11.1B
2026 Q2 filing
| Ticker | Company | Weight | Shares | Change |
|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS Corp | 13.52% | 2,777,777 | ADDED (+5.6%) |
| ASND | Ascendis Pharma A/S | 12.24% | 5,111,111 | NEW |
| KRYS | Krystal Biotech, Inc. | 9.64% | 2,888,888 | HELD |
| MDGL | MADRIGAL PHARMACEUTICALS INC | 8.84% | 1,833,333 | ADDED (+0.8%) |
| ARGX | ARGENX SE - ADR | 8.33% | 1,000,000 | HELD |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | 8.31% | 11,355,555 | ADDED (+6.1%) |
| KYMR | KYMERA THERAPEUTICS INC | 7.70% | 7,474,747 | HELD |
| RVMD | REVOLUTION MEDICINES INC | 3.86% | 2,297,000 | TRIMMED (-2.0%) |
| CYTK | CYTOKINETICS INC | 3.82% | 4,999,999 | ADDED (+50.0%) |
| CELC | Celcuity Inc. | 3.19% | 3,400,000 | ADDED (+0.7%) |
| GPCR | STRUCTURE THERAPEUTICS INC | 3.16% | 6,555,555 | HELD |
| XENE | XENON PHARMACEUTICALS INC | 3.13% | 5,777,777 | HELD |
| DFTX | DEFINIUM THERAPEUTICS INC | 3.04% | 7,188,888 | ADDED (+43.8%) |
| QURE | uniQure N.V. | 2.78% | 6,727,777 | ADDED (+12.9%) |
| VERA | VERA THERAPEUTICS INC | 2.21% | 5,723,888 | TRIMMED (-2.8%) |
| TSHA | Taysha Gene Therapies, Inc. | 1.46% | 23,888,888 | ADDED (+10.1%) |
| OCUL | OCULAR THERAPEUTIX INC | 1.11% | 12,540,000 | ADDED (+1.8%) |
| DMRA | Damora Therapeutics, Inc. | 0.88% | 3,783,000 | HELD |
| COAG | HEMAB THERAPEUTICS HOLDINGS | 0.63% | 1,925,150 | NEW |
| GHRS | GH Research PLC | 0.43% | 1,800,000 | HELD |
| VRDN | Viridian Therapeutics, Inc.\DE | 0.41% | 2,500,000 | ADDED (+66.7%) |
| SEPN | SEPTERNA INC | 0.40% | 1,337,500 | HELD |
| AVTX | AVALO THERAPEUTICS INC | 0.39% | 2,333,333 | ADDED (+65.5%) |
| FTH | FAETH THERAPEUTICS INC | 0.32% | 1,444,039 | NEW |
| WHWK | WHITEHAWK THERAPEUTICS INC | 0.12% | 2,849,402 | HELD |
| LXEO | LEXEO THERAPEUTICS INC | 0.06% | 1,489,189 | TRIMMED (-20.6%) |
Exited this quarter: ALKS, ASND, CELC, MNKD, UTHR.
Source: SEC Form 13F filing for the quarter ended Jun 30, 2026, filed Aug 14, 2026. CIK 0001633313. Change labels compare with the fund’s previous quarterly filing. 13F filings cover long positions only.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.